BioNTech SE (XBUL:22UA) Beta: N/A (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBUL:22UA BioNTech SE XBUL:22UA
61 GF Score
Price лв88.20
GF Value лв71.55
! 5 Warning Signs
View Full Analysis

What is BioNTech SE Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-09-09), BioNTech SE's Beta is Not available.

BioNTech SE  (XBUL:22UA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

BioNTech SE Beta Related Terms

BioNTech SE Beta Historical Data

* Premium members only.

The historical data trend for BioNTech SE's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNTech SE Beta Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BioNTech SE Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XBUL:22UA
61GF Score
BioNTech SE XBUL:22UA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioNTech SE Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is BioNTech SE (XBUL:22UA) Overvalued in 2026?

Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued. The current stock price of лв88.20 is trading 23.3% above its estimated GF Value™ of лв71.55.

Key valuation signals for XBUL:22UA:

  • Beta: N/A
  • GF Value™: лв71.55 vs. price of лв88.20 (23.3% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the XBUL:22UA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioNTech SE Business Description

Address An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
61GF Score

Get the complete analysis for XBUL:22UA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

лв88.20
Price
лв71.55
GF Value